Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin versus heparin in elderly patients undergoing elective PCI
ChiCTR1800016783Phase 4Completed
- Sponsor
- Panzhihua Central Hospital
- Start
- May 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of bivalirudin and heparin in coronary arteriosclerosis (2 arms), sponsored by Panzhihua Central Hospital. Primary endpoints: 30-day bleeding events after PCI and Adverse cardiovascular events within 30 days after PCI. Started May 2018; status: completed.
02
Drugs
bivalirudinheparin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1800016783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016783.